ArticleBMJ open2020
Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases.
Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
204 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Serial cycle threshold to assess the infectious potential of SARS-CoV-2: A systematic review.Epidemiology and infection · 2026Pooled it
- Diagnostic performance of CO-RADS for COVID-19: a systematic review and meta-analysis.European radiology · 2022Pooled it
- Combining and comparing regional SARS-CoV-2 epidemic dynamics in Italy: Bayesian meta-analysis of compartmental models and global sensitivity analysis.Frontiers in public health · 2022Pooled it
- Presymptomatic transmission of SARS-CoV-2 infection: a secondary analysis using published data.BMJ open · 2021Pooled it
- Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications.European journal of epidemiology · 2020Pooled it
- SARS-CoV-2 detection, viral load and infectivity over the course of an infection.The Journal of infection · 2020Pooled it
- Generation time in a discrete epidemic model with asymptomatic carriers: beyond geometric waiting times.Infectious Disease Modelling · 2027Article
- Resolving parameter uncertainty in SIR models through population-level serological surveillance: A synthetic study.Infectious Disease Modelling · 2026Article
- Automated model discovery based on COVID-19 epidemiological data from Thuringia, Germany.PloS one · 2026Article
- SARS-CoV-2 infection in dogs, dog owners, dog breeders, and veterinarians in the Ashanti and Greater Accra regions of Ghana-zoonotic implications.Frontiers in veterinary science · 2026Article
- Understanding pandemics through molecular gas dynamics.PNAS nexus · 2025Article
- Effectiveness of different border control strategies for reducing mpox importation risk: a modelling study.The Lancet regional health. Southeast Asia · 2025Article
- Impact of non-pharmacological interventions on the first wave of COVID-19 in Portugal 2020.Heliyon · 2025Article
- COVID-19 clinical presentation, management, and epidemiology: a concise compendium.Frontiers in public health · 2025Review
- Modelling the potential spread of Clade Ib MPXV in Asian cities.BMJ public health · 2025Article
- Article
- Cognitively-plausible reinforcement learning in epidemiological agent-based simulations.Frontiers in epidemiology · 2025Article
- Article
- Evolutionary and epidemic dynamics of COVID-19 in Germany exemplified by three Bayesian phylodynamic case studies.Bioinformatics and biology insights · 2025Article
- Article
144 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOur objective was to review the literature on the inferred duration of the infectious period of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, and provide an overview of the variation depending on the methodological approach.
designRapid scoping review. Literature review with fixed search terms, up to 1 April 2020. Central tendency and variation of the parameter estimates for infectious period in (A) asymptomatic and (B) symptomatic cases from (1) virological studies (repeated testing), (2) tracing studies and (3) modelling studies were gathered. Narrative review of viral dynamics. INFORMATION SOURCES: Search strategies developed and the following searched: PubMed, Google Scholar, MedRxiv and BioRxiv. Additionally, the Health Information Quality Authority (Ireland) viral load synthesis was used, which screened literature from PubMed, Embase, ScienceDirect, NHS evidence, Cochrane, medRxiv and bioRxiv, and HRB open databases.
resultsThere was substantial variation in the estimates, and how infectious period was inferred. One study provided approximate median infectious period for asymptomatic cases of 6.5-9.5 days. Median presymptomatic infectious period across studies varied over <1-4 days. Estimated mean time from symptom onset to two negative RT-PCR tests was 13.4 days (95% CI 10.9 to 15.8) but was shorter when studies included children or less severe cases. Estimated mean duration from symptom onset to hospital discharge or death (potential maximal infectious period) was 18.1 days (95% CI 15.1 to 21.0); time to discharge was on average 4 days shorter than time to death. Viral dynamic data and model infectious parameters were often shorter than repeated diagnostic data.
conclusionsThere are limitations of inferring infectiousness from repeated diagnosis, viral loads and viral replication data alone and also potential patient recall bias relevant to estimating exposure and symptom onset times. Despite this, available data provide a preliminary evidence base to inform models of central tendency for key parameters and variation for exploring parameter space and sensitivity analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.